Edastar (Edaravone) 1.5 mg/mL: An Antioxidant Neuroprotectant for the Management of Acute Ischemic Stroke and Amyotrophic Lateral Sclerosis

Oxidative stress constitutes one of the pivotal pathogenic links in both acute cerebrovascular catastrophes and chronic neurodegenerative processes. Edastar is a pharmaceutical preparation delivering edaravone at a concentration of 1.5 mg/mL. Each 20 mL ampoule carries 30 mg of the active substance. In contrast to the majority of neuroprotective agents that operate through receptor-mediated mechanisms, edaravone acts at a fundamental biochemical level — it intercepts and neutralizes free radicals before they can initiate the irreversible cascade of neuronal and vascular endothelial cell membrane destruction.

🧬 Mechanism of Action: Direct Free-Radical Elimination

During an acute cerebrovascular event — whether ischemic or hemorrhagic in nature — a cascade of pathological biochemical events unfolds within the brain parenchyma. The central event in this cascade is a dramatic surge in the production of reactive oxygen species, most notably hydroxyl radicals (OH•). Paradoxically, the most powerful burst of radical generation occurs precisely at the moment of blood-flow restoration (reperfusion): the renewed supply of oxygen to previously ischemic tissue triggers an aberrant upregulation of arachidonic acid metabolism and of the enzyme systems that generate free radicals.

The aggressive molecular species thus produced launch an attack on the polyunsaturated fatty acid chains that constitute the phospholipids of cell membranes. A self-propagating chain reaction of lipid peroxidation is set in motion, in which a single radical molecule is capable of destroying hundreds of lipid molecules. The membrane loses its barrier function, a process that culminates in escalating cerebral edema, widespread neuronal death, and the progressive worsening of neurological deficit.

Edaravone functions as a highly effective free-radical scavenger. It engages in direct chemical interaction with hydroxyl and peroxyl radicals, transforming them into stable, non-reactive compounds. In parallel, the drug suppresses the lipid peroxidation chain reaction, thereby shielding both neuronal and endothelial cell membranes from oxidative destruction. A critical advantage of edaravone over many other antioxidants is its well-documented ability to traverse the blood-brain barrier and to exert its effects directly within the cerebral tissue.

In amyotrophic lateral sclerosis (ALS) — a disease whose precise etiology remains incompletely elucidated — the accrual of oxidative damage within motor neurons is regarded as one of the principal drivers of their progressive demise. By attenuating the intensity of the oxidative assault, edaravone slows the tempo of neurodegeneration, a benefit that is clinically expressed as the prolonged preservation of motor function and of the capacity for self-care.

📋 Clinical Indications

Edastar is deployed in two fundamentally distinct clinical scenarios:

1. Acute Ischemic Stroke and Transient Ischemic Attack.

• Goal: reduction of the cerebral ischemic injury volume and prevention of the formation of a fixed post-stroke neurological deficit.
• A non-negotiable prerequisite for efficacy is the earliest possible initiation of therapy — ideally, within the first 24 hours of symptom onset.

2. Amyotrophic Lateral Sclerosis (ALS).

• Goal: retardation of functional deterioration in patients with a confirmed diagnosis of ALS.
• The drug does not cure the disease, but it is capable of extending the period of motor independence and enhancing quality of life.

💉 Administration Protocol: Two Regimens for Two Pathologies

For Acute Ischemic Stroke:

• Single dose: 30 mg (1 ampoule) twice daily — morning and evening.
• Route of administration: intravenous infusion delivered over exactly 30 minutes.
• Working solution preparation: the contents of a single ampoule are diluted in 100 mL of 0.9% sodium chloride solution.
• Duration of therapy: no fewer than 14 days. Depending on the patient's clinical condition, the course may be abbreviated at the discretion of the treating physician.

For ALS:

• Single dose: 60 mg (2 ampoules) once daily.
• Route of administration: intravenous infusion delivered over 60 minutes.
• Preparation: the contents of two ampoules are diluted in a sufficient volume of 0.9% sodium chloride.
• Cyclic Treatment Regimen:
  • First Course: 14 days of daily infusions, followed by a full 14-day rest period. The total duration of one course amounts to 28 days.
  • Second and All Subsequent Courses: 10 days of infusions within a 14-day window, succeeded by a 14-day rest period.

⚠️ Contraindications and Mandatory Precautionary Measures

Absolute Contraindications:

• Severe renal failure.
• Hypersensitivity to edaravone or any constituent of the solution (including sodium metabisulfite E223).
• Pediatric population — clinical experience is absent; the safety profile has not been established.

Use During Pregnancy and Lactation:

• The safety of edaravone administration during pregnancy has not been ascertained. Prescription to pregnant women is not recommended.
• Edaravone is excreted into breast milk. Women must discontinue breastfeeding entirely for the duration of therapy.

Special Considerations for Elderly Patients:
In geriatric individuals, physiological functions are globally diminished; against this background, the risk of serious adverse events — including fatal outcomes — is statistically elevated. Surveillance of such patients must be especially rigorous throughout the entire treatment period.

Critical Pharmaceutical Incompatibility Rules:

Edaravone enters into chemical interactions with a range of substances, necessitating the strictest adherence to preparation and administration protocols:

• Admixture with any infusion solutions containing sugars (glucose, fructose, dextrose, etc.) is categorically prohibited — this leads to a decline in edaravone concentration.
• Admixture with parenteral nutrition solutions and amino acid mixtures is strictly forbidden.
• Co-administration through the same infusion line with anticonvulsant agents (diazepam, phenytoin sodium, and others) is prohibited due to the risk of insoluble precipitate formation.
• Concomitant administration with potassium canrenoate is not permitted.
• Upon parallel prescription of antibiotics with a predominantly renal excretory pathway (cefazolin sodium, cefotiam hydrochloride, piperacillin sodium, etc.), regular laboratory monitoring of renal function is mandatory.

📊 Adverse Reaction Profile

Given the broad spectrum of potential complications, Edastar therapy is conducted exclusively in an inpatient hospital setting under continuous medical observation. Reported adverse events include:

• Renal and Urinary System: acute renal failure, nephrotic syndrome.
• Skin and Subcutaneous Tissue: rash, redness, swelling, pruritus, erythema.
• Hepatobiliary System: hepatic dysfunction, hepatic failure, fulminant hepatitis, jaundice.
• Nervous System: insomnia, headache.
• Cardiovascular System: elevation of blood pressure.
• Blood and Lymphatic System: agranulocytosis, disseminated intravascular coagulation (DIC), decreased erythrocyte count, leukocytosis, leukopenia, decreased hematocrit and hemoglobin, thrombocytosis, thrombocytopenia.
• Respiratory System: acute lung injury syndrome (accompanied by pyrexia, cough, dyspnea, and characteristic chest X-ray abnormalities).
• Gastrointestinal Tract: nausea, vomiting.
• Musculoskeletal System: rhabdomyolysis.
• Immune System: shock, anaphylactic shock (manifesting as urticaria, hypotension, and respiratory difficulty).
• Laboratory Parameters: elevated serum levels of ALT, AST, LDH, γ-glutamyl transpeptidase, bilirubin, creatinine, and uric acid; glycosuria, hematuria, proteinuria.
• Injection-Site Reactions: redness and swelling at the infusion site.
• General Disorders: hyperthermia.

📦 Storage Conditions

Ampoules must be stored exclusively in the original cardboard packaging at a temperature not exceeding 25 °C (77 °F). The storage location must be dry, protected from light, and wholly inaccessible to children. The shelf life of the preparation is 2 years from the date of manufacture.

📦Find out about the delivery to your country on WhatsApp